Ardent Health Partners stock initiated with Buy rating at UBS

UBS initiated coverage on Ardent Health Partners (ARDT) with a Buy rating and a $17 price target, asserting that the stock's 21.08% year-to-date decline is an overreaction and that its current valuation (6.32x P/E, 6.95x EV/EBITDA, and 4.5x 2026 EV/EBITDAR) represents an attractive entry point significantly below industry averages. The firm anticipates ARDT will achieve revenue growth comparable to peers with superior margin improvement potential, despite the company reporting strong Q2 2025 results with $0.52 EPS and $1.65 billion revenue (+11.9% YoY), which included a substantial one-time benefit. This positive outlook from UBS contrasts with JPMorgan's recent adjustment of its price target lower to $15, while maintaining a Neutral rating.

Analysis

UBS has initiated coverage on Ardent Health Partners (ARDT) with a 'Buy' rating and a $17.00 price target, presenting a strong bull case centered on valuation. The firm argues that the stock's 21.08% year-to-date decline represents an excessive market reaction to long-term Medicaid payment reductions. Ardent's current valuation is positioned as highly attractive, with a P/E ratio of 6.32x and a 2026 estimated EV/EBITDAR multiple of 4.5x, significantly below the typical 7-9x range for hospital peers. UBS contends that even if all supplemental payments were excluded, the resulting 6.0x multiple would still represent a discount. This valuation argument is supported by Ardent's strong Q2 2025 performance, where revenue grew 11.9% year-over-year to $1.65 billion and EPS of $0.52 surpassed expectations. However, it is crucial to note that this quarter included a one-time $65 million EBITDA benefit; excluding this, core revenue growth was in the mid-single digits, aligning with management's guidance. The bullish outlook from UBS is contrasted by JPMorgan's more cautious stance, which recently reduced its price target on ARDT from $18.00 to $15.00 while maintaining a 'Neutral' rating, highlighting a clear divergence in analyst sentiment.

Key Decisions for Investors

• Investors should consider the bull case presented by UBS, which frames Ardent Health Partners as a value opportunity based on its significant valuation discount to peers and the view that recent stock declines are an overreaction.
• It is critical to dissect the company's earnings by separating the one-time $65 million EBITDA benefit from core operational performance to accurately assess its underlying growth and margin improvement potential.
• Monitor the divergence between UBS's 'Buy' rating at a $17 target and JPMorgan's 'Neutral' rating with a lower $15 target, as a convergence in analyst sentiment could serve as a major catalyst or risk factor for the stock.